The AHSN network is supporting the NHS Accelerated Access Collaborative to help NHS organisations overcome practical obstacles and increase adoption of rapid uptake products (RUPs).
These proven innovations are approved by NICE and have been selected as products that support the NHS Long Term Plan’s key clinical priorities but have lower than expected uptake to date.
The Pathway Transformation Fund (PTF) is available to provide financial support to integrate these products into everyday practice and address issues such as pathway redesign, training staff on how to use new equipment or establishing new data collection methods.
Applications for funding opened on 4 January 2021, and the deadline has been extended until 30 April 2021 in recognition on pressures on healthcare services amidst the coronavirus pandemic.
Eastern AHSN is happy to support local NHS partners in their applications for funding, which will be reviewed by the NHS Accelerated Access Collaborative as they are received to manage capacity within the review process, so it is encouraged that applications are entered as soon as they are ready. Results will be fed back to applicants in May.
The Rapid Uptake Product (RUP) for lipid management is a novel, NICE-approved clinical pathway. This innovation aims to improve a person’s lipid profile, by reducing cholesterol concentration in blood by treating patients with the right medicine along the evidence-based pathway. The pathway includes three medicines: high intensity statins (HIST), ezetimibe, and PCSK9 inhibitors (continued from 2019/20).
FeNO testing is a method of diagnosing asthma by measuring fractional exhaled nitric oxide (FeNO) in the breath of patients suspected of having asthma. The aim of this innovation will be to improve patient care and outcomes by more effective diagnosis of patients suspected of having asthma.
Biological therapies can transform patient lives by reducing long-term side effects of other treatments (e.g. oral corticosteroids (OCS)) and can also reduce the number of exacerbations and life-threatening asthma attacks. The aim of this innovation will be to improve patient care and outcomes by providing a better treatment option for patients with severe asthma.
The aim of this innovation is to improve patient care and outcomes by effectively providing chemoprevention in women at risk of developing breast cancer.
More information is available on the NHS Accelerated Access Collaborative website.
Get faster access to the latest innovations and technologies to deliver excellent patient careFind out more